Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention

SONG Ying TANG Xiao Fang YAO Yi HE Chen XU Jing Jing WANG Huan Huan GAO Zhan WANG Miao YUAN Jin Qing

SONG Ying, TANG Xiao Fang, YAO Yi, HE Chen, XU Jing Jing, WANG Huan Huan, GAO Zhan, WANG Miao, YUAN Jin Qing. Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention[J]. Biomedical and Environmental Sciences, 2017, 30(12): 898-906. doi: 10.3967/bes2017.120
Citation: SONG Ying, TANG Xiao Fang, YAO Yi, HE Chen, XU Jing Jing, WANG Huan Huan, GAO Zhan, WANG Miao, YUAN Jin Qing. Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention[J]. Biomedical and Environmental Sciences, 2017, 30(12): 898-906. doi: 10.3967/bes2017.120

doi: 10.3967/bes2017.120
基金项目: 

grant from the National Natural Science Foundation of China 81470486

Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention

Funds: 

grant from the National Natural Science Foundation of China 81470486

More Information
    Author Bio:

    SONG Ying, female, born in 1983, Master, Attending Physician, majoring in cardiology

    Corresponding author: YUAN Jin Qing, Tel:86-10-88322455, Fax:86-10-68351786, E-mail:dr_jinqingyuan@sina.com
    • 关键词:
    •  / 
    •  / 
    •  / 
    •  / 
    •  
  • Figure  1.  Flow diagram describing the study population.

    Figure  2.  ADP inhibition according to ADRA2A genotype stratified by sex.

    Table  1.   Allele and Genotype Frequency of ADRA2A Genetic Variants

    Characteristics RS11195419 N (%) RS3750625 N (%) RS553668 N (%) RS13306146 N (%)
    Allele frequency, n = 2, 048
      Major allele 1, 677 (81.9) 1, 695 (82.8) 1, 160 (56.6) 1, 528 (74.6)
      Minor allele 371 (18.1) 353 (17.2) 888 (43.4) 520 (25.4)
    Genotype frequency, n = 1, 024
      Wild type 682 (66.6) 700 (68.4) 334 (32.6) 587 (57.3)
      Heterozygote 313 (30.6) 295 (28.8) 492 (48.0) 354 (34.6)
      Homozygote 29 (2.8) 29 (2.8) 198 (19.3) 83 (8.1)
    下载: 导出CSV

    Table  2.   Baseline Characteristics by ADRA2A Genotypes (rs11195419 and rs3750625)

    Variables RS11195419 RS3750625
    WT
    (N = 682)
    HE
    (N = 313)
    HO
    (N = 29)
    P WT
    (N = 700)
    HE
    (N = 295)
    HO
    (N = 29)
    P
    Age, years 58.2 ± 10.6 59.2 ± 11.6 59.0 ± 7.6 0.692 58.2 ± 10.6 59.2 ± 10.6 59.8 ± 8.2 0.273
    Male, n (%) 525 (77.0) 227 (72.5) 21 (72.4) 0.293 537 (76.7) 216 (73.2) 20 (69.0) 0.358
    BMI, kg/m2 26.0 ± 3.2 26.2 ± 3.2 25.8 ± 3.7 0.739 26.0 ± 3.2 26.2 ± 3.3 26.0 ± 3.7 0.531
    Platelet, × 109/L 206.4 ± 53.3 204.3 ± 56.7 183.8 ± 55.4 0.089 207.0 ± 53.5 202.2 ± 56.0 189.2 ± 61.1 0.126
    ACS, n (%) 228 (33.4) 92 (29.4) 6 (20.7) 0.190 232 (32.1) 88 (29.8) 6 (20.7) 0.252
    DM, n (%)
 186 (27.3) 110 (35.1) 12 (41.4) 0.017 192 (27.4) 104 (35.3) 12 (41.4) 0.020
    Hypertension, n (%) 425 (62.3) 192 (61.3) 16 (55.2) 0.725 436 (62.3) 180 (61.0) 17 (58.6) 0.873
    HCL, n (%) 573 (84.0) 270 (86.3) 22 (75.9) 0.285 589 (84.1) 254 (86.1) 22 (75.9) 0.318
    Current smoking, n (%) 261 (38.3) 114 (36.4) 8 (27.6) 0.463 267 (38.1) 109 (36.9) 7 (24.1) 0.306
    CHD family history, n (%) 7 (1.0) 4 (1.3) 1 (3.4) 0.484 7 (1.0) 4 (1.4) 1 (3.4) 0.458
    Previous MI, n (%) 124 (18.2) 45 (14.4) 5 (17.2) 0.332 127 (18.1) 41 (13.9) 6 (20.7) 0.230
    Previous PCI, n (%) 103 (15.1) 39 (12.5) 5 (17.2) 0.491 103 (14.7) 39 (13.2) 5 (17.2) 0.749
    Previous CABG, n (%) 3 (0.4) 2 (0.6) 0 (0) 0.852 3 (0.4) 2 (0.7) 0 (0) 0.814
    LAD, n (%) 379 (55.6) 192 (61.3) 20 (69.0) 0.107 386 (55.1) 185 (62.7) 20 (69.0) 0.040
    LCX, n (%) 197 (28.9) 90 (28.8) 7 (24.1) 0.858 204 (29.1) 82 (27.8) 8 (27.6) 0.904
    RCA, n (%) 314 (46.0) 141 (45.0) 11 (37.9) 0.678 322 (46.0) 133 (45.1) 11 (37.9) 0.684
    LM, n (%) 31 (4.5) 19 (6.1) 0 (0) 0.272 32 (4.6) 18 (6.1) 0 (0) 0.275
    Statin, n (%) 663 (97.2) 302 (96.5) 29 (100) 0.522 681 (97.3) 284 (96.3) 29 (100.0) 0.438
    β-blocker, n (%) 604 (88.6) 278 (88.8) 27 (93.1) 0.750 621 (88.7) 261 (88.5) 27 (93.1) 0.750
    ACEI/ARB, n (%) 408 (59.8) 183 (58.5) 13 (44.8) 0.268 418 (59.7) 173 (58.6) 13 (44.8) 0.277
    CCB, n (%) 256 (37.5) 129 (41.2) 8 (27.6) 0.260 264 (37.7) 121 (41.0) 8 (27.6) 0.297
    PPIs, n (%) 115 (16.9) 43 (13.7) 4 (13.8) 0.435 120 (17.1) 38 (12.9) 4 (13.8) 0.232
    DES, n (%) 676 (99.1) 311 (99.4) 29 (100) 0.821 694 (99.1) 293 (99.3) 29 (100.0) 0.852
    BMS, n (%) 5 (0.7) 1 (0.3) 0 (0) 0.668 5 (0.7) 1 (0.3) 0 (0) 0.713
    Ballooning only, n (%) 1 (0.1) 1 (0.3) 0 (0) 0.824 1 (0.1) 1 (0.3) 0 (0) 0.791
    Note. WT: Wild Type, HE: Heterozygote, HO: Homozygote, ADRA2A: the α2A-adrenergic receptor gene, BMI: body mass index, ACS: acute coronary syndrome, DM: diabetes mellitus, CHD: coronary heart disease, HCL: Hypercholesterolemia, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, LAD:left anterior descendens, LCX: left circumflex, RCA: right coronary artery, ACEI: angiotensin conversion enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, PPI: proton pump inhibitor, DES: Drug-eluting stent, BMS: Bare mental stent.
    下载: 导出CSV

    Table  3.   Association of ADP Inhibition with ADRA2A Genotypes

    SNPs ADP Inhibition, % Additive Model P Value Additive Model Adjusted P Value AA Inhibition, % Additive Model P Value Additive Model Adjusted P Value
    Wild type Heterozygote Homozygote Wild type Heterozygote Homozygote
    RS11195419 54.2 ± 29.7 50.7 ± 27.7 39.3 ± 19.5 0.011 0.022 88.5 ± 20.0 89.3 ± 18.9 85.3 ± 20.7 0.351 1.404
    RS3750625 54.0 ± 29.8 51.1 ± 27.4 37.5 ± 18.6 0.004 0.016 88.8 ± 19.3 88.8 ± 19.8 85.4 ± 20.7 0.356 0.712
    RS13306146 51.8 ± 28.1 54.3 ± 30.3 52.1 ± 29.4 0.857 0.857 87.6 ± 21.0 90.0 ± 17.7 90.3 ± 18.1 0.428 0.571
    RS553668 52.3 ± 30.1 54.4 ± 29.3 50.5 ± 27.7 0.812 1.083 87.6 ± 19.9 89.3 ± 20.0 88.9 ± 19.0 0.810 0.810
    Note. SNP: single nucleotide polymorphism; ADP: adenosine diphosphate, AA: arachidonic acid.
    下载: 导出CSV

    Table  4.   Allele, Geneotype Frequency and Association of ADP Inhibition with CYP2C19*2

    Allele Frequency
    (N = 2, 048)
    N (%) Genotype Frequency (N = 1, 024) N (%) ADP Inhibition , % P Value
    Major allele 1, 391 (67.9) Wild type 474 (46.3) Wild type 55.2 ± 28.7
    Minor allele 657 (32.1) Heterozygote 443 (43.3) Heterozygote 51.7 ± 28.9 0.005
    Homozygote 107 (10.4) Homozygote 45.5 ± 29.2
    Note. ADP: adenosine diphosphate.
    下载: 导出CSV

    Table  5.   Association of ADRA2A SNPs with ADP Inhibition by Multivariate Linear Regression Analysis

    Variables RS11195419 RS3750625
    Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
    Coef (95% CI) P Coef (95% CI) P Coef (95% CI) P Coef (95% CI) P
    SNPs -2.5 (-24.5 to -3.1) 0.011 -2.1 (-21.3 to -1.0) 0.033 -2.5 (-24.5 to -3.1) 0.011 -2.3 (-22.3 to -2.0) 0.020
    CYP2C19*2 -2.7 (-13.8 to -2.2) 0.007 -3.1 (14.3 to -3.3) 0.002 -2.7 (-13.8 to -2.2) 0.007 -3.1 (-14.3 to -3.3) 0.002
    Male 6.8 (10.0 to -18.1) < 0.001 4.2 (5.1 to 13.9) < 0.001 6.8 (10.0 to -18.1) < 0.001 4.2 (5.0 to 13.9) < 0.001
    Age (year) -4.4 (-0.5 to -0.2) < 0.001 -2.8 (-0.4 to -0.1) 0.005 -4.4 (-0.5 to -0.2) < 0.001 -2.8 (-0.4 to -0.1) 0.005
    BMI (kg/m2) 2.3 (0.1 to 1.2) 0.018 2.0 (0.1 to 1.1) 0.047 2.3 (0.1 to 1.2) 0.018 2.0 (0.1 to 1.1) 0.043
    Hypertension -2.8 (-8.8 to -1.5) 0.006 -2.0 (-8.0 to -0.1) 0.047 -2.8 (-8.8 to -1.5) 0.006 -2.0 (-7.9 to -0.2) 0.049
    Hypercholesterolemia 2.10 (0.3 to 10.1) 0.036 2.0 (0.1 to 9.5) 0.044 2.10 (0.3 to 10.1) 0.036 2.0 (0.1 to 9.4) 0.045
    Acute coronary syndrome 4.5 (5.03 to 12.9) < 0.001 3.5 (3.1 to 10.7) < 0.001 4.5 (5.03 to 12.9) < 0.001 3.5 (3.1 to 10.7) < 0.001
    Note. SNP: single nucleotide polymorphism; BMI: body mass index.
    下载: 导出CSV

    Table  6.   Association of ADRA2A SNPs and ADP Inhibition by Univariate and Multivariate Linear Regression Analysis Stratificated by Sex

    Characteristics Univariate Analysis Multivariate Analysis
    Coef (95% CI) P Coef (95% CI) P
    Male
      RS11195419 -2.9 (-31.3 to -6.3) 0.003 -2.6 (-28.6 to -4.2) 0.008
      RS3750625 -3.2 (-33.3 to -7.8) 0.002 -2.8 (-30.4 to -5.5) 0.005
    Female
      RS11195419 0.9 (-17.9 to 19.7) 0.928 0.1 (-17.5 to 20.2) 0.890
      RS3750625 -0.2 (-19.2 to 16.3) 0.872 -0.1 (-19.2 to 16.6) 0.889
    下载: 导出CSV

    Appendix.   Baseline characteristics by ADRA2A genotypes (rs553668 and rs13306146)

    Variables RS553668 RS13306146
    WT
    (N = 334)
    HE
    (N = 492)
    HO
    (N = 198)
    P WT
    (N = 587)
    HE
    (N = 354)
    HO
    (N = 83)
    P
    Age, years 59.1 ± 10.0 58.1 ± 10.4 58.6 ± 11.7 0.343 58.5 ± 10.2 58.6 ± 10.8 58.3 ± 12.3 0.974
    Male, n (%) 242 (72.5) 385 (78.3) 146 (73.7) 0.134 438 (74.6) 269 (76.0) 66 (79.5) 0.601
    BMI, kg/m2 26.1 ± 3.2 26.1 ± 3.2 25.9 ± 3.3 0.703 26.2 ± 3.2 25.9 ± 3.3 26.0 ± 3.6 0.325
    Platelet, ×109/L 203.0 ± 52.2 202.5 ± 53.8 214.8 ± 59.2 0.019 202.8 ± 52.9 205.9 ± 54.9 217.3 ± 62.7 0.071
    ACS, n (%) 98 (29.3) 159 (32.3) 69 (34.8) 0.399 175 (29.8) 116 (32.8) 35 (42.2) 0.070
    DM, n (%)
 116 (34.7) 141 (28.7) 51 (25.8) 0.059 189 (32.2) 99 (28.0) 20 (24.1) 0.181
    Hypertension, n (%) 218 (65.3) 288 (58.5) 127 (64.1) 0.112 362 (61.7) 222 (62.7) 49 (59.0) 0.820
    HCL, n (%) 285 (85.3) 414 (84.1) 166 (83.8) 0.866 494 (84.2) 299 (84.5) 72 (86.7) 0.830
    Current smoking, n (%) 118 (35.3) 202 (41.1) 63 (31.8) 0.048 218 (37.1) 135 (38.1) 30 (36.1) 0.925
    CHD family history, n (%) 4 (1.2) 4 (0.8) 4 (2.0) 0.411 9 (1.5) 2 (0.6) 1 (1.2) 0.409
    Previous MI, n (%) 50 (15.0) 98 (19.9) 26 (13.1) 0.049 102 (17.4) 61 (17.2) 11 (13.3) 0.638
    Previous PCI, n (%) 44 (13.2) 76 (15.4) 27 (13.6) 0.625 85 (14.5) 50 (14.1) 12 (14.5) 0.988
    Previous CABG, n (%) 1 (0.3) 4 (0.8) 0 (0) 0.319 3 (0.5) 2 (0.6) 0 (0) 0.796
    LAD, n (%) 199 (59.6) 273 (55.5) 119 (60.1) 0.379 349 (59.5) 190 (53.7) 52 (62.7) 0.140
    LCX, n (%) 95 (28.4) 140 (28.5) 59 (29.8) 0.932 170 (29.0) 103 (29.1) 21 (25.3) 0.773
    RCA, n (%) 151 (45.2) 227 (46.1) 88 (44.4) 0.913 263 (44.8) 168 (47.5) 35 (42.2) 0.597
    LM, n (%) 17 (5.1) 22 (4.5) 11 (5.6) 0.818 29 (4.9) 18 (5.1) 3 (3.6) 0.851
    Statin, n (%) 328 (98.2) 473 (96.1) 193 (97.5) 0.210 567 (96.6) 345 (97.5) 82 (98.8) 0.466
    β-blocker, n (%) 293 (87.7) 438 (89.0) 178 (89.9) 0.722 522 (88.9) 312 (88.1) 75 (90.4) 0.832
    ACEI/ARB, n (%) 205 (61.4) 285 (57.9) 114 (57.6) 0.554 341 (58.1) 214 (60.5) 49 (59.0) 0.776
    PPIs, n (%) 66 (13.4) 58 (17.4) 38 (19.2) 0.109 94 (16.0) 55 (15.5) 13 (15.7) 0.980
    DES, n (%) 331 (99.1) 488 (99.2) 197 (99.5) 0.878 584 (99.5) 350 (98.9) 82 (98.8) 0.522
    BMS, n (%) 1 (0.3) 4 (0.8) 1 (0.5) 0.629 1 (0.2) 4 (1.1) 1 (1.2) 0.130
    Ballooning only, n (%) 2 (0.6) 0 (0) 0 (0) 0.126 2 (0.3) 0 (0) 0 (0) 0.474
    Note.*: P < 0.005; WT: Wild Type, HE: Heterozygote, HO: Homozygote, ADRA2A: the α2A-adrenergic receptor gene, BMI: body mass index, ACS: acute coronary syndrome, DM: diabetes mellitus, CHD: coronary heart disease, HCL: Hypercholesterolemia, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, LAD:left anterior descendens, LCX: left circumflex, RCA: right coronary artery, ACEI: angiotensin conversion enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, PPI: proton pump inhibitor, DES: Drug-eluting stent, BMS: Bare mental stent.
    下载: 导出CSV
  • [1] Mangiacapra F, De Bruyne B, Muller O, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv, 2010; 3, 35-40. doi:  10.1016/j.jcin.2009.10.024
    [2] Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 2011; 306, 1215-23. doi:  10.1001/jama.2011.1332
    [3] Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J, 2009; 157, 818-24, 24 e1. doi:  10.1016/j.ahj.2009.02.012
    [4] Chiu FC, Wang TD, Lee JK, et al. Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention. Eur J Intern Med, 2011; 22, 471-7. doi:  10.1016/j.ejim.2011.02.021
    [5] Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation, 2009; 120, 2214-21. doi:  10.1161/CIRCULATIONAHA.109.883454
    [6] Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol, 2007; 49, 1505-16. doi:  10.1016/j.jacc.2006.11.044
    [7] Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP Ⅲa and response to aspirin and clopidogrel. Thromb Res, 2007; 119, 355-60. doi:  10.1016/j.thromres.2006.02.006
    [8] Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009; 360, 363-75. doi:  10.1056/NEJMoa0808227
    [9] Saydam F, Degirmenci I, Birdane A, et al. The CYP2C19*2 and CYP2C19*2017; 121, 29-36.
    [10] Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 2009; 119, 2553-60. doi:  10.1161/CIRCULATIONAHA.109.851949
    [11] Wallentin L, James S, Storey RF, et al. Effect of CYP2C19*2010; 376, 1320-8.
    [12] Mayer K, Orban M, Bernlochner I, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015; 26, 53-8. doi:  10.3109/09537104.2013.863857
    [13] Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest, 1996; 26, 353-70. doi:  10.1046/j.1365-2362.1996.150293.x
    [14] Colombo A, Proietti R, Culic V, et al. Triggers of acute myocardial infarction: a neglected piece of the puzzle. J Cardiovasc Med, 2014; 15, 1-7. doi:  10.2459/JCM.0b013e3283641351
    [15] Freeman K, Farrow S, Schmaier A, et al. Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens, 1995; 8, 863-9. doi:  10.1016/0895-7061(95)00155-I
    [16] Peace AJ, Mangiacapra F, Bailleul E, et al. alpha2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant. Arterioscler Thromb Vasc Biol, 2014; 34, 1314-9. doi:  10.1161/ATVBAHA.114.303275
    [17] Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost, 2008; 6, 2027-34. doi:  10.1111/jth.2008.6.issue-12
    [18] Cuisset T, Hamilos M, Delrue M, et al. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. Thromb Haemost, 2010; 103, 774-9. doi:  10.1160/TH09-06-0355
    [19] Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J, 2010; 31, 2501-55. doi:  10.1093/eurheartj/ehq277
    [20] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011; 124, e574-651. doi:  10.1161/CIR.0b013e31823ba622
    [21] Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets, 2007; 18, 497-505. doi:  10.1080/09537100701329162
    [22] Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 2005; 106, 2723-9. doi:  10.1182/blood-2005-03-1290
    [23] Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Eng J Med, 1985; 313, 1315-22. doi:  10.1056/NEJM198511213132103
    [24] Andrews NP, Gralnick HR, Merryman P, et al. Mechanisms underlying the morning increase in platelet aggregation: a flow cytometry study. J Am Coll Cardiol, 1996; 28, 1789-95. doi:  10.1016/S0735-1097(96)00398-1
    [25] Mustonen P, van Willigen G, Lassila R. Epinephrine-via activation of p38-MAPK--abolishes the effect of aspirin on platelet deposition to collagen. Thromb Res, 2001; 104, 439-49. doi:  10.1016/S0049-3848(01)00388-7
    [26] Keularts IM, van Gorp RM, Feijge MA, et al. alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem, 2000; 275, 1763-72. doi:  10.1074/jbc.275.3.1763
    [27] Maayani S, Schwarz T, Craddock-Royal B, et al. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets, 2001; 12, 359-75. doi:  10.1080/09537100120078403
    [28] Beres BJ, Toth-Zsamboki E, Vargova K, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost, 2008; 100, 829-38. https://www.ncbi.nlm.nih.gov/pubmed/?term=Analysis+of+platelet+alpha2-adrenergic+receptor+activity+in+stable+coronary+artery+disease+patients+on+dual+antiplatelet+therapy.
    [29] Kiive E, Kurrikoff T, Maestu J, et al. Effect of alpha2A-adrenoceptor C-1291G genotype and maltreatment on hyperactivity and inattention in adolescents. Prog Neuro-psychopharmacol Biol Psychiatry, 2010; 34, 219-24. doi:  10.1016/j.pnpbp.2009.11.011
    [30] Tamm G, Kreegipuu K, Harro J. Perception of emotion in facial stimuli: The interaction of ADRA2A and COMT genotypes, and sex. Prog Neuro-psychopharmacol Biol Psychiatry, 2016; 64, 87-95. doi:  10.1016/j.pnpbp.2015.07.012
    [31] Yee DL, Bergeron AL, Sun CW, et al. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost, 2006; 4, 2043-50. doi:  10.1111/jth.2006.4.issue-9
  • [1] LIAO Zhen Yu, YANG Shuo, HU Song, LIU Jia, MAO Yong Jun, SUN Shu Qin.  Association between Gene Polymorphisms and SNP-SNP Interactions of the Matrix Metalloproteinase 2 Signaling Pathway and the Risk of Vascular Senescence . Biomedical and Environmental Sciences, 2024, 37(2): 146-156. doi: 10.3967/bes2024.016
    [2] CHEN Xi, CHEN Hao, LU Wei Bo, ZHANG Min, TAO Yuan, WANG Qing Cheng, FU Guo Sheng, ZHANG Wen Bin.  Lower Baseline LDL Cholesterol Affects All-cause Mortality in Patients with First Percutaneous Coronary Intervention . Biomedical and Environmental Sciences, 2023, 36(4): 324-333. doi: 10.3967/bes2023.038
    [3] XU Ze, ZHANG Dong Dong, LIU Ya Ping, ZHANG Yu Jing, XUE Yuan, GAO Jiao Jiao, ZHAO Tong, HUANG Hao Yue, LI Wen Jie, LI Xing.  Association of VDR Polymorphisms and Gene–obesity Interaction with Type 2 Diabetes: A Case–control Study among Chinese Rural Population . Biomedical and Environmental Sciences, 2022, 35(11): 1074-1078. doi: 10.3967/bes2022.136
    [4] LIU Ru, GAO Li Jian, XU Ou, ZHANG Ce, JIA Si Da, QIAO Shu Bin, YANG Yue Jin, GAO Run Lin, XU Bo, YUAN Jin Qing.  Does Percutaneous Coronary Intervention on Off Days have an Effect on Long-term Prognosis in Patients with Coronary Artery Disease in China? . Biomedical and Environmental Sciences, 2021, 34(5): 387-394. doi: 10.3967/bes2021.051
    [5] LU Yi, Abdus Samee, WANG Jin, WANG Fu Ru, TANG Shao Wen, YANG Ming Wen, YE Sen, LI Jin Shuang, GONG Xiao Xuan, LI Yong, LI Chun Jian.  Preliminary Study on the Efficacy of a New Zero-load X-ray Protector for Coronary Intervention . Biomedical and Environmental Sciences, 2020, 33(11): 867-871. doi: 10.3967/bes2020.118
    [6] LIU Ru, GAO Zhan, GAO Li Jian, ZHAO Xue Yan, CHEN Jue, QIAO Shu Bin, YANG Yue Jin, GAO Run Lin, XU Bo, YUAN Jin Qing.  Risk or Beneficial Factors Associated with Unplanned Revascularization Risk Following Percutaneous Coronary Intervention: A Large Single-Center Data . Biomedical and Environmental Sciences, 2020, 33(6): 431-443. doi: 10.3967/bes2020.058
    [7] HAN Han, ZHAO Ming Xu, WANG Yan, WANG Jun, REN Bing Nan, GE Hui Na, WANG Teng, SUN Bei Bei, BA Yue, LI Wen Jie.  Significant Polymorphisms of Vitamin D Receptor Gene (rs2189480 and rs3847987) Related to the Risk of Type 2 Diabetes in Henan Rural Area . Biomedical and Environmental Sciences, 2019, 32(1): 58-62. doi: 10.3967/bes2019.009
    [8] WANG Yan, HAN Han, WANG Jun, SHEN Fang, YU Fei, WANG Ling, YU Song Cheng, ZHANG Dong Dong, SUN Hua Lei, XUE Yuan, BA Yue, WANG Chong Jian, LI Wen Jie.  Polymorphisms in CYP2R1 Gene Associated with Serum Vitamin D Levels and Status in a Chinese Rural Population . Biomedical and Environmental Sciences, 2019, 32(7): 550-553. doi: 10.3967/bes2019.072
    [9] WANG Bo Shen, XU Kai, ZHANG Hong, PU Yue Pu, YIN Li Hong, HAN Lei, CHEN Lin, WANG Ning, ZHU Bao Li, ZHANG Juan.  Association between NFE2L2 Gene Polymorphisms and Noise-induced Hearing Loss in a Chinese Population . Biomedical and Environmental Sciences, 2019, 32(6): 465-470. doi: 10.3967/bes2019.063
    [10] XU Jing Jing, JIANG Lin, XU Lian Jun, GAO Zhan, ZHAO Xue Yan, ZHANG Yin, SONG Ying, LIU Ru, SUN Kai, GAO Run Lin, XU Bo, SONG Lei, YUAN Jin Qing.  Association of CDKN2B-AS1 Polymorphisms with Premature Triple-vessel Coronary Disease and Their Sex Specificity in the Chinese Population . Biomedical and Environmental Sciences, 2018, 31(11): 787-796. doi: 10.3967/bes2018.106
    [11] ZHAO Xue Yan, LI Jian Xin, TANG Xiao Fang, XU Jing Jing, SONG Ying, JIANG Lin, CHEN Jue, SONG Lei, GAO Li Jian, GAO Zhan, QIAO Shu Bin, YANG Yue Jin, GAO Run Lin, XU Bo, YUAN Jin Qing.  Prognostic Value of NT-proBNP in Stable Coronary Artery Disease in Chinese Patients after Percutaneous Coronary Intervention in the Drug-eluting Stent Era . Biomedical and Environmental Sciences, 2018, 31(12): 859-866. doi: 10.3967/bes2018.117
    [12] ZHANG Qun, LIU Di, ZHAO ZhongYao, SUN Qi, DING LiXiang, WANG YouXin.  Association between the SUMO4 M55V Polymorphism and Susceptibility to Type 2 Diabetes Mellitus: A Meta-analysis . Biomedical and Environmental Sciences, 2017, 30(4): 288-295. doi: 10.3967/bes2017.038
    [13] ZHOU Jun Mei, ZHANG Ming, WANG Shu, WANG Bing Yuan, HAN Cheng Yi, REN Yong Cheng, ZHANG Lu, ZHANG Hong Yan, YANG Xiang Yu, ZHAO Yang, HU Dong Sheng.  Association of the ADIPOQ Rs2241766 and Rs266729 Polymorphisms with Metabolic Syndrome in the Chinese Population:A Meta-analysis . Biomedical and Environmental Sciences, 2016, 29(7): 505-515. doi: 10.3967/bes2016.066
    [14] ZHOU Xuan, XIANG Ding Cheng, ZENG Jing, YI Shao Dong, ZHANG Jin Xia, LI Dan Hui.  Lack of Association between Genetic Polymorphisms Affecting Autonomic Activity and Coronary Artery Spasm . Biomedical and Environmental Sciences, 2013, 26(8): 689-692. doi: 10.3967/0895-3988.2013.08.010
    [15] WANG Qiang, BAI Xue Tao, XU Dong Qun, LI Hong, XU Chun Yu, FANG Jian Long.  Association of Polymorphisms of STAT6 and SO2 with Chinese Childhood Asthma: a Case-control Study . Biomedical and Environmental Sciences, 2011, 24(6): 670-677. doi: 10.3967/0895-3988.2011.06.012
    [16] HU Ying, CHEN ErJun, MU Yue, LI JinLu, CHEN RenJi.  BHMT Gene Polymorphisms as Risk Factors for Cleft Lip and Cleft Palate in a Chinese Population . Biomedical and Environmental Sciences, 2011, 24(2): 89-93. doi: 10.3967/0895-3988.2011.02.001
    [17] TIAN-JIAO CHEN, CHENG-YE JI, XIAO-YING ZHENG, YONG-HUA HU.  Association of β3 Adrenergic Receptor and Peroxisome Proliferator-activated Receptor Gamma 2 Polymorphisms With Insulin Sensitivity: A Twin Study . Biomedical and Environmental Sciences, 2007, 20(2): 99-105.
    [18] WEI-YAN ZHAO, JIAN-FENG HUANG, LAI-YUAN WANG, HONG-FAN LI, PENG-HUA ZHANG, QI ZHAO, SHU-FENG CHEN, DONG-FENG GU.  Association of the Apolipoprotein B Gene Polymorphisms With Essential Hypertension in Northern Chinese Han Population . Biomedical and Environmental Sciences, 2007, 20(3): 260-264.
    [19] XIAO-HONG ZHAO, GUANG JIA, YONG-QUAN LIU, SHAO-WEI LIU, LEI YAN, YU JIN, NIAN LIU.  Association Between Polymorphisms of DNA Repair Gene XRCC1 and DNA Damage in Asbestos-Exposed Workers . Biomedical and Environmental Sciences, 2006, 19(3): 232-238.
    [20] SUN Hong-xia, ZHANG KUI-XING, DU WEI-NAN, SHI JIN-XIU, JIANG ZHENG-WEN, SUN HAO, ZUO JIN, HUANG WEI, CHEN ZHU, SHEN YAN, YAO Zhi-Jian, QIANG Bo-Qin, FANG FU-DE.  Single Nucleotide Polymorphisms in CAPN10 Gene of Chinese People and Its Correlation With Type 2 Diabetes Mellitus in Han People of Northern China . Biomedical and Environmental Sciences, 2002, 15(1): 75-82.
  • 加载中
图(2) / 表ll (7)
计量
  • 文章访问数:  1335
  • HTML全文浏览量:  386
  • PDF下载量:  47
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-03-23
  • 录用日期:  2017-12-01
  • 刊出日期:  2017-12-01

Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention

doi: 10.3967/bes2017.120
    基金项目:

    grant from the National Natural Science Foundation of China 81470486

    作者简介:

    SONG Ying, female, born in 1983, Master, Attending Physician, majoring in cardiology

    通讯作者: YUAN Jin Qing, Tel:86-10-88322455, Fax:86-10-68351786, E-mail:dr_jinqingyuan@sina.com

English Abstract

SONG Ying, TANG Xiao Fang, YAO Yi, HE Chen, XU Jing Jing, WANG Huan Huan, GAO Zhan, WANG Miao, YUAN Jin Qing. Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention[J]. Biomedical and Environmental Sciences, 2017, 30(12): 898-906. doi: 10.3967/bes2017.120
Citation: SONG Ying, TANG Xiao Fang, YAO Yi, HE Chen, XU Jing Jing, WANG Huan Huan, GAO Zhan, WANG Miao, YUAN Jin Qing. Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention[J]. Biomedical and Environmental Sciences, 2017, 30(12): 898-906. doi: 10.3967/bes2017.120
    • Platelet inhibition shows wide inter-individual variation in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), despite the administration of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. High residual platelet reactivity (HRPR) is associated with increased short-and long-term risk of cardiovascular ischemic events, such as myocardial infarction and in stent thrombosis[1-5]. The individual variability of antiplatelet response to clopidogrel may be related to environmental factors, such as patients' noncompliance and drug interactions[6]. However, genetic polymorphism plays crucial roles. Cytochrome P450 2C19 (CYP2C19) polymorphism is linked to clopidogrel responsiveness and ischemic events in ACS patients or PCI-treated subjects[7-9]. With the introduction of more potent purinergic receptor P2Y12 antagonists, such as prasugrel or ticagrelor, the individual antiplatelet variability has been reduced[10-11], but substantial variability still exists[12], suggesting that other genetic polymorphisms are the underlying cause of the response variability of this class of antiplatelet drugs. Circulating catecholamine plays an important role in platelet function through the activation of α2A-AR on platelet membrane surface[13-14]. The α2A-AR is encoded by ADRA2A on chromosome 10. In healthy volunteers, a genetic variant (6.3-kb variant) of ADRA2A is responsible for the increased platelet reactivity with catecholamine[15]. Peace AJ et al.[16]demonstrated that α2A-AR promotes P2Y12 receptor functionality and contributes to HRPR in stable coronary artery disease in patients taking DAPT with aspirin and clopidogrel[17]. However, Cuisset T et al.[18] reported that the 6.3-kb variant of ADRA2A did not show any major impact on residual platelet reactivity in ACS patients. Therefore, the interaction between the genetic variants of ADRA2A and platelet reactivity with DAPT is still unclear. This study aims to examine the potential association of ADRA2A genetic variants with residual platelet reactivity in Chinese patients on DAPT undergoing PCI.

    • Study Population Patients presenting to the Fuwai Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College between March 1, 2011, and March 30, 2013, were consecutively enrolled in this prospective observational study. Inclusion criteria for enrollment were patients with coronary heart disease (CHD) who have undergone PCI. The exclusion criteria were: age < 18 years; hemodynamic instability; active bleeding and bleeding diatheses; use of glycoprotein IIb/IIIa inhibitor; oral anticoagulation therapy; usage of intensified antiplatelet agents other than the standard DAPT with aspirin and clopidogrel; contraindication to antiplatelet therapy; non-cardiac disease with a life expectancy of < 1 year; disagreement with platelet function test and ADRA2A genotyping; or inability to follow the protocol. The Institutional Review Board approved the study protocols, and the patients provided written informed consent for participation.

      Study Design If patients was not taking long-term aspirin or clopidogrel, they received a 300-mg loading dose of clopidogrel and 300-mg loading dose of aspirin at least 12 h before undergoing PCI, followed by 75 mg/day clopidogrel for 1 year and 100 mg/day maintenance dose of aspirin for life. The decision for PCI was based on the coronary angiography results and all interventions were conducted according to the 2010 European Society of Cardiology/ European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization[19], and 2011 American College of Cardiology/American Heart Association Task Force on Clinical Practice/ Society for Cardiovascular Angiography and Interventions (ACCF/AHA/SCAI) guidelines for PCI[20]. The types of stents used were chosen by the operators. Anticoagulation with low molecular weight heparin (enoxaparin) or unfractionated heparin was initiated before angiography in all patients. The flow diagram for the trial is shown in Figure 1.

      Figure 1.  Flow diagram describing the study population.

      Genotyping Four single nucleotide polymorphisms (SNPs) ADRA2A were selected based on the analysis of HapMap and Chinese Han Beijing Databank using Haploview 4.2 software. HapMap selection criteria included minor allele frequency to be greater than 0.05. Blood samples were obtained from a peripheral vein from each patient and stored in 4 mL evacuated collection tubes containing ethylenediaminetetraacetic acid (EDTA). Genomic DNA was extracted from white blood cells according to the standard salting-out method and was stored in 200 μL of TE (10 mmol/L Tris/HCl and 1.0 mmol/L EDTA, pH 8.0). The selected ADRA2A SNPs were rs11195419 (C > A), rs13306146 (A > G), rs553668 (A > G), rs3750625 (C > A), and CYP2C19*2 rs4244285 (G > A) were genotyped using the ligase detection reaction (LDR) and a commercially available detection system (ABI 3730XL DNA Analyzer System; Applied Biosystems, Foster City, CA, USA). Repeat genotyping was performed on random duplicate samples (n = 45), and Sanger sequencing was used for quality control.

      Thromboelastograph Platelet Mapping Assay Blood was collected in evacuated collection tubes, containing 3.2% trisodium citrate and the inner walls coated with lithium heparin, 12-24 h after undergoing PCI. A predetermined volume of blood was drawn, and the tube was inverted 3-5 times to ensure complete mixing with the anticoagulant. Modified thromboelastography (TEG®) uses four channels to detect the effects of antiplatelet therapy via the arachidonic acid (AA) and adenosine diphosphate (ADP) pathways. A detailed description of this method has been outlined previously[21]. The TEG Hemostasis Analyzer (Haemonetics Corp, Braintree, MA, USA) and automated analytical software were used to measure the physical properties.

      The average percentage of platelet inhibition by clopidogrel was computed as the contribution of ADP-stimulated platelets to the maximal clot strength (ADP inhibition) by the TEG software: 100 -100 × [(MAAA or ADP-MAfibrin)/ (MAthrombin-MAfibrin)], where MAAA is the AA-induced clot strength (measurement of the aspirin effect), MAADP is the ADP-induced clot strength (measurement of the ADP effect), MAfibrin is the activator-induced clot strength (measurement of the fibrin contribution), and MAthrombin is the thrombin-induced clot strength (maximum clot strength).

      Statistical Analysis Continuous variables were expressed as mean ± standard deviation (SD) and compared using Student's t-test or one-way analysis of variance (ANOVA) was appropriate. After demonstrating significant differences among variables by the ANOVA test, post hoc comparisons between the groups were performed with the Student-Newman-Keuls test for multiple comparisons. Categorical variables were expressed as frequencies and percentages and were compared with a chi-square test (χ2) or Fisher's exact test. All SNPs evaluated in our study were tested for deviation from the Hardy-Weinberg equilibrium using the chi-square test. Any deviation between observed and expected frequencies was tested for significance using the χ2 test. Linear regression analysis was performed to assess the association between SNPs and ADP-induced platelet aggregation. Bonferroni correction was used to correct the multiple comparisons problem. In the multivariate model, we adjusted for potential confounders including CYP2C19*2, age, sex, BMI, platelets count, diabetes mellitus, hypertension, hypercholesterolemia, current smoking, ACS, angiotensin converting enzyme inhibitors/ angiotensin Ⅱ receptor blockers (ACEI/ARB), calcium channel blockers (CCB), statins, β-blocker, and PPIs use. Subgroup analyses were performed according to sex. Additive model was assumed to test the association between SNPs and ADP inhibition. Statistical analyses was mainly performed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA), and a two-tailed P value less than 0.05 was considered statistically significant.

    • From March 2011 to March 2013, 1, 024 patients who underwent PCI and received post intervention aspirin and clopidogrel, were enrolled in the study. All these patients also completed platelet function measures and genetic sampling tests. The minor allele frequencies of the ADRA2A SNPs (rs11195419, rs3750625, rs553668, and rs13306146) and CYP2C19*2 (rs4244285) were 18.1%, 17.2%, 43.7%, 25.4%, and 32.1%, respectively. The homozygous groups of the SNPs were 2.7%, 2.7%, 19.5%, 8.0%, and 10.4%, respectively. Genotypic distributions of these SNPs conformed with the Hardy-Weinberg equilibrium. The allele and genotype frequencies are reported in Table 1. The average age of the patients was 58.5 ± 10.5 years, and > 75% were males. Less than half of the patients presented with ACS (31.8%). PCIs were mostly performed using drug-eluting stents (99.2%). History of diabetes was significantly different across rs11195419 (P = 0.023) and rs3750625 (P = 0.023) genotypes. Platelets count (P = 0.019), current smoking history (P = 0.048), and previous myocardial infarction history (P = 0.049) were also significantly different across the rs553668 genotypes. The baseline characteristics of SNPs (rs11195419 and rs3750625) are presented in Table 2 and the SNPs (rs553668 and rs13306146) are reported in the Appendix (available in www. besjournal.com).

      Table 1.  Allele and Genotype Frequency of ADRA2A Genetic Variants

      Characteristics RS11195419 N (%) RS3750625 N (%) RS553668 N (%) RS13306146 N (%)
      Allele frequency, n = 2, 048
        Major allele 1, 677 (81.9) 1, 695 (82.8) 1, 160 (56.6) 1, 528 (74.6)
        Minor allele 371 (18.1) 353 (17.2) 888 (43.4) 520 (25.4)
      Genotype frequency, n = 1, 024
        Wild type 682 (66.6) 700 (68.4) 334 (32.6) 587 (57.3)
        Heterozygote 313 (30.6) 295 (28.8) 492 (48.0) 354 (34.6)
        Homozygote 29 (2.8) 29 (2.8) 198 (19.3) 83 (8.1)

      Table 2.  Baseline Characteristics by ADRA2A Genotypes (rs11195419 and rs3750625)

      Variables RS11195419 RS3750625
      WT
      (N = 682)
      HE
      (N = 313)
      HO
      (N = 29)
      P WT
      (N = 700)
      HE
      (N = 295)
      HO
      (N = 29)
      P
      Age, years 58.2 ± 10.6 59.2 ± 11.6 59.0 ± 7.6 0.692 58.2 ± 10.6 59.2 ± 10.6 59.8 ± 8.2 0.273
      Male, n (%) 525 (77.0) 227 (72.5) 21 (72.4) 0.293 537 (76.7) 216 (73.2) 20 (69.0) 0.358
      BMI, kg/m2 26.0 ± 3.2 26.2 ± 3.2 25.8 ± 3.7 0.739 26.0 ± 3.2 26.2 ± 3.3 26.0 ± 3.7 0.531
      Platelet, × 109/L 206.4 ± 53.3 204.3 ± 56.7 183.8 ± 55.4 0.089 207.0 ± 53.5 202.2 ± 56.0 189.2 ± 61.1 0.126
      ACS, n (%) 228 (33.4) 92 (29.4) 6 (20.7) 0.190 232 (32.1) 88 (29.8) 6 (20.7) 0.252
      DM, n (%)
 186 (27.3) 110 (35.1) 12 (41.4) 0.017 192 (27.4) 104 (35.3) 12 (41.4) 0.020
      Hypertension, n (%) 425 (62.3) 192 (61.3) 16 (55.2) 0.725 436 (62.3) 180 (61.0) 17 (58.6) 0.873
      HCL, n (%) 573 (84.0) 270 (86.3) 22 (75.9) 0.285 589 (84.1) 254 (86.1) 22 (75.9) 0.318
      Current smoking, n (%) 261 (38.3) 114 (36.4) 8 (27.6) 0.463 267 (38.1) 109 (36.9) 7 (24.1) 0.306
      CHD family history, n (%) 7 (1.0) 4 (1.3) 1 (3.4) 0.484 7 (1.0) 4 (1.4) 1 (3.4) 0.458
      Previous MI, n (%) 124 (18.2) 45 (14.4) 5 (17.2) 0.332 127 (18.1) 41 (13.9) 6 (20.7) 0.230
      Previous PCI, n (%) 103 (15.1) 39 (12.5) 5 (17.2) 0.491 103 (14.7) 39 (13.2) 5 (17.2) 0.749
      Previous CABG, n (%) 3 (0.4) 2 (0.6) 0 (0) 0.852 3 (0.4) 2 (0.7) 0 (0) 0.814
      LAD, n (%) 379 (55.6) 192 (61.3) 20 (69.0) 0.107 386 (55.1) 185 (62.7) 20 (69.0) 0.040
      LCX, n (%) 197 (28.9) 90 (28.8) 7 (24.1) 0.858 204 (29.1) 82 (27.8) 8 (27.6) 0.904
      RCA, n (%) 314 (46.0) 141 (45.0) 11 (37.9) 0.678 322 (46.0) 133 (45.1) 11 (37.9) 0.684
      LM, n (%) 31 (4.5) 19 (6.1) 0 (0) 0.272 32 (4.6) 18 (6.1) 0 (0) 0.275
      Statin, n (%) 663 (97.2) 302 (96.5) 29 (100) 0.522 681 (97.3) 284 (96.3) 29 (100.0) 0.438
      β-blocker, n (%) 604 (88.6) 278 (88.8) 27 (93.1) 0.750 621 (88.7) 261 (88.5) 27 (93.1) 0.750
      ACEI/ARB, n (%) 408 (59.8) 183 (58.5) 13 (44.8) 0.268 418 (59.7) 173 (58.6) 13 (44.8) 0.277
      CCB, n (%) 256 (37.5) 129 (41.2) 8 (27.6) 0.260 264 (37.7) 121 (41.0) 8 (27.6) 0.297
      PPIs, n (%) 115 (16.9) 43 (13.7) 4 (13.8) 0.435 120 (17.1) 38 (12.9) 4 (13.8) 0.232
      DES, n (%) 676 (99.1) 311 (99.4) 29 (100) 0.821 694 (99.1) 293 (99.3) 29 (100.0) 0.852
      BMS, n (%) 5 (0.7) 1 (0.3) 0 (0) 0.668 5 (0.7) 1 (0.3) 0 (0) 0.713
      Ballooning only, n (%) 1 (0.1) 1 (0.3) 0 (0) 0.824 1 (0.1) 1 (0.3) 0 (0) 0.791
      Note. WT: Wild Type, HE: Heterozygote, HO: Homozygote, ADRA2A: the α2A-adrenergic receptor gene, BMI: body mass index, ACS: acute coronary syndrome, DM: diabetes mellitus, CHD: coronary heart disease, HCL: Hypercholesterolemia, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, LAD:left anterior descendens, LCX: left circumflex, RCA: right coronary artery, ACEI: angiotensin conversion enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, PPI: proton pump inhibitor, DES: Drug-eluting stent, BMS: Bare mental stent.
    • The median level of ADP inhibition was 52.7% ± 29.0%. ADP inhibition was significantly different among genotypes with rs11195419 (adjusted P = 0.022) and rs3750625 (adjusted P = 0.016) in additive model and the homozygous groups of these SNPs had the lowest ADP inhibition (39.3% ± 19.5% and 37.5% ± 18.6%, respectively). However, there we did not observe differences in ADP inhibition among genotypes with rs13306146 and rs553668. We did not identify any association with AA inhibition and ADRA2A SNPs either (Table 3). We also found the ADP inhibition was significantly different according to the CYP2C*2 genotype (P = 0.005). (The allele, genotypes and ADP inhibition of CYP2C19*2 are presented in Table 4). We conducted a multivariate analysis including CYP2C19*2 genotype and other potential confounders to identify whether the two significantly associated SNPs of ADRA2A by univariate analysis were independently related to ADP inhibition. The multivariate analysis indicated that rs11195419 (95% CI: -21.3 to -1.0; P = 0.033) and rs3750625 (95% CI: -22.3 to -2.0; P = 0.020) were independent predictors of ADP inhibition (Table 5). A significant association of ADP inhibition was also observed with CYP2C19*2, male, age and hypertension.

      Table 3.  Association of ADP Inhibition with ADRA2A Genotypes

      SNPs ADP Inhibition, % Additive Model P Value Additive Model Adjusted P Value AA Inhibition, % Additive Model P Value Additive Model Adjusted P Value
      Wild type Heterozygote Homozygote Wild type Heterozygote Homozygote
      RS11195419 54.2 ± 29.7 50.7 ± 27.7 39.3 ± 19.5 0.011 0.022 88.5 ± 20.0 89.3 ± 18.9 85.3 ± 20.7 0.351 1.404
      RS3750625 54.0 ± 29.8 51.1 ± 27.4 37.5 ± 18.6 0.004 0.016 88.8 ± 19.3 88.8 ± 19.8 85.4 ± 20.7 0.356 0.712
      RS13306146 51.8 ± 28.1 54.3 ± 30.3 52.1 ± 29.4 0.857 0.857 87.6 ± 21.0 90.0 ± 17.7 90.3 ± 18.1 0.428 0.571
      RS553668 52.3 ± 30.1 54.4 ± 29.3 50.5 ± 27.7 0.812 1.083 87.6 ± 19.9 89.3 ± 20.0 88.9 ± 19.0 0.810 0.810
      Note. SNP: single nucleotide polymorphism; ADP: adenosine diphosphate, AA: arachidonic acid.

      Table 4.  Allele, Geneotype Frequency and Association of ADP Inhibition with CYP2C19*2

      Allele Frequency
      (N = 2, 048)
      N (%) Genotype Frequency (N = 1, 024) N (%) ADP Inhibition , % P Value
      Major allele 1, 391 (67.9) Wild type 474 (46.3) Wild type 55.2 ± 28.7
      Minor allele 657 (32.1) Heterozygote 443 (43.3) Heterozygote 51.7 ± 28.9 0.005
      Homozygote 107 (10.4) Homozygote 45.5 ± 29.2
      Note. ADP: adenosine diphosphate.

      Table 5.  Association of ADRA2A SNPs with ADP Inhibition by Multivariate Linear Regression Analysis

      Variables RS11195419 RS3750625
      Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
      Coef (95% CI) P Coef (95% CI) P Coef (95% CI) P Coef (95% CI) P
      SNPs -2.5 (-24.5 to -3.1) 0.011 -2.1 (-21.3 to -1.0) 0.033 -2.5 (-24.5 to -3.1) 0.011 -2.3 (-22.3 to -2.0) 0.020
      CYP2C19*2 -2.7 (-13.8 to -2.2) 0.007 -3.1 (14.3 to -3.3) 0.002 -2.7 (-13.8 to -2.2) 0.007 -3.1 (-14.3 to -3.3) 0.002
      Male 6.8 (10.0 to -18.1) < 0.001 4.2 (5.1 to 13.9) < 0.001 6.8 (10.0 to -18.1) < 0.001 4.2 (5.0 to 13.9) < 0.001
      Age (year) -4.4 (-0.5 to -0.2) < 0.001 -2.8 (-0.4 to -0.1) 0.005 -4.4 (-0.5 to -0.2) < 0.001 -2.8 (-0.4 to -0.1) 0.005
      BMI (kg/m2) 2.3 (0.1 to 1.2) 0.018 2.0 (0.1 to 1.1) 0.047 2.3 (0.1 to 1.2) 0.018 2.0 (0.1 to 1.1) 0.043
      Hypertension -2.8 (-8.8 to -1.5) 0.006 -2.0 (-8.0 to -0.1) 0.047 -2.8 (-8.8 to -1.5) 0.006 -2.0 (-7.9 to -0.2) 0.049
      Hypercholesterolemia 2.10 (0.3 to 10.1) 0.036 2.0 (0.1 to 9.5) 0.044 2.10 (0.3 to 10.1) 0.036 2.0 (0.1 to 9.4) 0.045
      Acute coronary syndrome 4.5 (5.03 to 12.9) < 0.001 3.5 (3.1 to 10.7) < 0.001 4.5 (5.03 to 12.9) < 0.001 3.5 (3.1 to 10.7) < 0.001
      Note. SNP: single nucleotide polymorphism; BMI: body mass index.

      Additional analysis stratified by sex showed that in male patients, ADP inhibition was significantly different among the genotypes carrying rs11195419 (P = 0.003) and rs3750625 (P = 0.002) in additive model, and the homozygous groups had the lowest ADP inhibition. However, this difference was not found in female patients (Figure 2). Multivariate analysis also showed that rs11195419 and rs3750625 were predictors of ADP inhibition (95% CI: -28.6 to -4.2; P = 0.008 and 95% CI: -30.4 to -5.5; P = 0.005, respectively) in male patients, which was not observed in female patients (Table 6).

      Figure 2.  ADP inhibition according to ADRA2A genotype stratified by sex.

      Table 6.  Association of ADRA2A SNPs and ADP Inhibition by Univariate and Multivariate Linear Regression Analysis Stratificated by Sex

      Characteristics Univariate Analysis Multivariate Analysis
      Coef (95% CI) P Coef (95% CI) P
      Male
        RS11195419 -2.9 (-31.3 to -6.3) 0.003 -2.6 (-28.6 to -4.2) 0.008
        RS3750625 -3.2 (-33.3 to -7.8) 0.002 -2.8 (-30.4 to -5.5) 0.005
      Female
        RS11195419 0.9 (-17.9 to 19.7) 0.928 0.1 (-17.5 to 20.2) 0.890
        RS3750625 -0.2 (-19.2 to 16.3) 0.872 -0.1 (-19.2 to 16.6) 0.889
    • This study has reported several important findings. 1) ADRA2A SNPs (rs11195419, rs3750625, rs553668, and rs13306146) commonly exists in Chinese populations. 2) The SNPs of rs11195419 and rs3750625 were significantly associated with ADP-induced platelet aggregation in Chinese patients treated with aspirin and clopidogrel who have undergone PCI. 3) The SNPs of rs11195419 and rs3750625 were independent predictors of ADP-induced platelet aggregation in Chinese patients, especially males.

    • To the best of our knowledge, this is the first study to report ADRA2A polymorphisms in Chinese CHD patients, and is found quite prevalent in the study cohort. Approximately one-third of our CHD patients were either heterozygous or homozygous for SNPs at rs11195419, rs13306146, and rs3750625. The SNP rs553668 was previously detected in approximately one-third of healthy volunteers, patients with ACS and stable CHD[15-16, 18]. In this study involving Chinese population with CHD, the polymorphism of rs553668 was much more common. The frequency of the mutated allele A at rs553668 was 43.7% and more than half of the patients were either heterozygous or homozygous genotype.

    • Epinephrine is an important mediator of platelet aggregation by stimulating α2A-AR on the membrane surface. It is demonstrated that healthy volunteers exhibit higher platelet reactivity in response to epinephrine compared with another agonist such as ADP[22]. There is an increased platelet aggregation amplified by increased levels of circulating catecholamines in the first 3 h after arising and keeping the upright posture, consistent with an increased risk of the cardiovascular event at the same time[23-24]. The α2A-AR is a G protein-coupled receptor on platelet membrane surfaces. The activation of α2A-AR results in a reduction of the cyclic adenosine monophosphate (cAMP) level and release of cytosolic phospholipase-A2 (PLA2) and AA, which are essential to the aggregation of the platelet[25]. Meanwhile, unlike other cell types, the occupation of the G protein -coupled α2A-AR receptors on platelets does not result in phospholipase C activation, but rather in the modulation of the Ca2+ response by relieving cAMP-mediated suppression of InsP3-dependent Ca2+-induced Ca2+ release (CICR)[26]. A previous study[27] reported that in the presence of P2Y12 receptor blockade, activation of α2A-AR contributed to platelet aggregation response. It is also known that similar to the P2Y12 receptor (also a G protein-coupled receptor), α2A-AR activation causes deceleration of the deaggregation component and shifts the balance toward increased aggregation in platelets reactivity, and thus may increase thrombotic risk in certain disease states in healthy volunteers. In healthy volunteers, α2A-AR directly promotes platelet aggregability and a more functional P2Y12 receptor in vitro[27]. α2A-AR also contributes to HRPR in stable coronary artery disease patients taking DAPT with aspirin and clopidogrel[17]. The α2A-AR activity triggers platelet aggregation and may contribute to cardiovascular events despite DAPT[28]. It was also observed that patients with increased platelet aggregation in response to epinephrine had increased platelet aggregation in response to ADP. However, this significant interaction between epinephrine and ADP-induced platelet aggregation was not observed with other platelet activators, such as collagen, AA, and thrombin receptor-activating peptide. Therefore, this significant interaction of the two pathways may explain the effect of α2A-AR on HPPR with DAPT. ADRA2A is a protein-coding gene, 3, 876 bases pair long, which is located at chromosome 10 at 10q24-q26. This gene encodes α2A-AR and contains no introns in either of its coding or untranslated sequences. The markedly heterogeneous platelet aggregation in CHD patients on DAPT induced by epinephrine indicates that different α2A-AR functions might be dictated by ADRA2A genetic polymorphisms. To our knowledge, the current study was the first to find an association of ADRA2A polymorphisms with ADP-induced platelet aggregation in Chinese patients administered aspirin and clopidogrel and undergoing PCI. In univariate analysis, we found that the minor allele A at rs11195419 and rs3750625 was significantly associated with lower ADP inhibition. Peace et al.[16] reported a null effect of rs553668 on ADP-induced platelet aggregation, which was confirmed in our study. We also demonstrated the CYP2C19*2 genotypes and included it in multivariate analysis to find the influence of both CYP2C19 and ADRA2A SNPs on platelet reactivity. Multivariate linear regression model also confirmed the findings. The ADRA2A SNPs (rs11195419 and rs3750625) and CYP2C19*2 were both independent predictors of ADP inhibition. All SNPs in the current study were located at three prime untranslated regions (3′-UTR), suggesting the functional importance of 3′-UTR of ADRA2A in ADP-induced platelet aggregation. However, the underlying mechanism of the effect of these SNPs on α2A-AR function and platelet aggregation is still unclear and needs further investigation.

    • The α2A-ARs are the most prevalent adrenergic receptors in the brain, including cerebral cortex and locus coeruleus. Previous research found that ADRA2A SNPs were associated with inattention. In particular, ADRA2A C-1291G showed sex-specific association with attention deficit/hyperactivity syndrome symptoms in boys and girls[29] and with the perception of emotion in facial stimuli in males and females[30]. Although these studies focused on ADRA2A gene in the nervous system, they also showed that ADRA2A SNPs might have gender-specific effects. In our study, we found a gender-specific association of ADRA2A genotypes with ADP-induced platelets aggregation; males rather than females had low ADP inhibition with the minor allele at rs11195419 and rs3750625. According to the findings of multivariate analysis, sex was the strongest predictor of ADP inhibition (P < 0.0001). We conducted a subgroup analysis to determine the co-effect of sex and SNPs in ADP inhibition. In the subgroup analysis, we found that in male patients, ADP inhibition was significantly associated with rs11195419 and rs3750625 genotypes both in the univariate and multivariate analysis. However, we did not find the same association in female patients. The underlying mechanism of this phenomenon is still unknown. The α2A-ARs prevail on the platelet membrane, through which catecholamines potentiate the effects of other agonists (such as ADP). Previous studies have suggested that interaction of epinephrine with α2A-ARs occurs in the early phase of platelet activation, which is followed by platelet aggregation and is modulated by multiple pathways[31]. The higher basal level of catecholamines in males relative to females might cause platelet hyper-reactivity, which might be modulated by ADRA2A genotypes at rs11195419 and rs3750625. Therefore, despite the use of aspirin and clopidogrel, the later phase of ADP-induced platelet aggregation was still amplified in males compared with females, resulting in lower ADP inhibition on antiplatelet regimens. It may also explain the platelet hyper-reactivity during treatments in male patients carrying specific α2A-ARs SNPs. However, a larger sample size is needed and the exact underlying mechanism warrants further investigation.

      Study Limitations There are several limitations of the current study. First, this is an observational study and platelet function was only evaluated by the TEG platelet mapping assay. Second, the mechanism of ADP inhibition and epinephrine-induced platelet aggregation remains unclear in the current study and it was difficult to explain the underlying mechanism of how the ADRA2A genotype might influence ADP-induced platelet aggregation, especially in males. Third, our investigation lacks a replication cohort. Lastly, the current study lacks the clinical follow-up to investigate the effect of ADRA2A SNPs on cardiovascular outcomes. Multi-centric, large, prospective clinical studies involving different ethnic populations to assess the clinical outcomes of high platelet reactivity are warranted in future.

    • ADRA2A genetic variations were associated with ADP-induced platelet aggregation during administration of DAPT in Chinese patients undergoing PCI and the effect was more pronounced in males.

    • No conflict of interest to declare.

    • Table Appendix.  Baseline characteristics by ADRA2A genotypes (rs553668 and rs13306146)

      Variables RS553668 RS13306146
      WT
      (N = 334)
      HE
      (N = 492)
      HO
      (N = 198)
      P WT
      (N = 587)
      HE
      (N = 354)
      HO
      (N = 83)
      P
      Age, years 59.1 ± 10.0 58.1 ± 10.4 58.6 ± 11.7 0.343 58.5 ± 10.2 58.6 ± 10.8 58.3 ± 12.3 0.974
      Male, n (%) 242 (72.5) 385 (78.3) 146 (73.7) 0.134 438 (74.6) 269 (76.0) 66 (79.5) 0.601
      BMI, kg/m2 26.1 ± 3.2 26.1 ± 3.2 25.9 ± 3.3 0.703 26.2 ± 3.2 25.9 ± 3.3 26.0 ± 3.6 0.325
      Platelet, ×109/L 203.0 ± 52.2 202.5 ± 53.8 214.8 ± 59.2 0.019 202.8 ± 52.9 205.9 ± 54.9 217.3 ± 62.7 0.071
      ACS, n (%) 98 (29.3) 159 (32.3) 69 (34.8) 0.399 175 (29.8) 116 (32.8) 35 (42.2) 0.070
      DM, n (%)
 116 (34.7) 141 (28.7) 51 (25.8) 0.059 189 (32.2) 99 (28.0) 20 (24.1) 0.181
      Hypertension, n (%) 218 (65.3) 288 (58.5) 127 (64.1) 0.112 362 (61.7) 222 (62.7) 49 (59.0) 0.820
      HCL, n (%) 285 (85.3) 414 (84.1) 166 (83.8) 0.866 494 (84.2) 299 (84.5) 72 (86.7) 0.830
      Current smoking, n (%) 118 (35.3) 202 (41.1) 63 (31.8) 0.048 218 (37.1) 135 (38.1) 30 (36.1) 0.925
      CHD family history, n (%) 4 (1.2) 4 (0.8) 4 (2.0) 0.411 9 (1.5) 2 (0.6) 1 (1.2) 0.409
      Previous MI, n (%) 50 (15.0) 98 (19.9) 26 (13.1) 0.049 102 (17.4) 61 (17.2) 11 (13.3) 0.638
      Previous PCI, n (%) 44 (13.2) 76 (15.4) 27 (13.6) 0.625 85 (14.5) 50 (14.1) 12 (14.5) 0.988
      Previous CABG, n (%) 1 (0.3) 4 (0.8) 0 (0) 0.319 3 (0.5) 2 (0.6) 0 (0) 0.796
      LAD, n (%) 199 (59.6) 273 (55.5) 119 (60.1) 0.379 349 (59.5) 190 (53.7) 52 (62.7) 0.140
      LCX, n (%) 95 (28.4) 140 (28.5) 59 (29.8) 0.932 170 (29.0) 103 (29.1) 21 (25.3) 0.773
      RCA, n (%) 151 (45.2) 227 (46.1) 88 (44.4) 0.913 263 (44.8) 168 (47.5) 35 (42.2) 0.597
      LM, n (%) 17 (5.1) 22 (4.5) 11 (5.6) 0.818 29 (4.9) 18 (5.1) 3 (3.6) 0.851
      Statin, n (%) 328 (98.2) 473 (96.1) 193 (97.5) 0.210 567 (96.6) 345 (97.5) 82 (98.8) 0.466
      β-blocker, n (%) 293 (87.7) 438 (89.0) 178 (89.9) 0.722 522 (88.9) 312 (88.1) 75 (90.4) 0.832
      ACEI/ARB, n (%) 205 (61.4) 285 (57.9) 114 (57.6) 0.554 341 (58.1) 214 (60.5) 49 (59.0) 0.776
      PPIs, n (%) 66 (13.4) 58 (17.4) 38 (19.2) 0.109 94 (16.0) 55 (15.5) 13 (15.7) 0.980
      DES, n (%) 331 (99.1) 488 (99.2) 197 (99.5) 0.878 584 (99.5) 350 (98.9) 82 (98.8) 0.522
      BMS, n (%) 1 (0.3) 4 (0.8) 1 (0.5) 0.629 1 (0.2) 4 (1.1) 1 (1.2) 0.130
      Ballooning only, n (%) 2 (0.6) 0 (0) 0 (0) 0.126 2 (0.3) 0 (0) 0 (0) 0.474
      Note.*: P < 0.005; WT: Wild Type, HE: Heterozygote, HO: Homozygote, ADRA2A: the α2A-adrenergic receptor gene, BMI: body mass index, ACS: acute coronary syndrome, DM: diabetes mellitus, CHD: coronary heart disease, HCL: Hypercholesterolemia, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, LAD:left anterior descendens, LCX: left circumflex, RCA: right coronary artery, ACEI: angiotensin conversion enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, PPI: proton pump inhibitor, DES: Drug-eluting stent, BMS: Bare mental stent.
参考文献 (31)

目录

    /

    返回文章
    返回